XBiotech (NASDAQ:XBIT) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of XBiotech (NASDAQ:XBIT) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

XBiotech Trading Up 1.4 %

XBIT stock opened at $4.36 on Friday. The business’s 50-day moving average price is $4.33 and its two-hundred day moving average price is $4.73. The firm has a market cap of $132.70 million, a PE ratio of -3.66 and a beta of 1.27. XBiotech has a 1-year low of $3.00 and a 1-year high of $6.69.

Hedge Funds Weigh In On XBiotech

A number of institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its position in XBiotech by 21.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 17,600 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 3,146 shares during the last quarter. Geode Capital Management LLC grew its position in shares of XBiotech by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 155,083 shares of the biopharmaceutical company’s stock valued at $544,000 after purchasing an additional 3,342 shares during the last quarter. Swiss National Bank grew its position in shares of XBiotech by 8.8% in the first quarter. Swiss National Bank now owns 46,800 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 3,800 shares during the last quarter. PDT Partners LLC grew its position in shares of XBiotech by 29.9% in the second quarter. PDT Partners LLC now owns 16,976 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,912 shares during the last quarter. Finally, BlackRock Inc. grew its position in shares of XBiotech by 1.6% in the third quarter. BlackRock Inc. now owns 258,934 shares of the biopharmaceutical company’s stock valued at $938,000 after purchasing an additional 4,002 shares during the last quarter. Institutional investors and hedge funds own 11.45% of the company’s stock.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.